SEC Form 4 · accession 0001209191-15-039558
Auspex Pharmaceuticals, Inc. · ASPX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Phillip M Schneider
Director
Period of report
May 5, 2015
Accepted (ET)
May 6, 2015 · 6:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001454189
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $12.00 | May 5, 2015 | D | 13,333 | D | — | Feb 2, 2024 | Common Stock | 13,333 | 0 | D |
| Stock Option (Right to Buy)F1 | $18.13 | May 5, 2015 | D | 6,667 | D | — | May 5, 2024 | Common Stock | 6,667 | 0 | D |
Explanation of responses
- F1Pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated March 29, 2015, among the Issuer, Teva Pharmaceuticals Industries Ltd. ("Parent"), and Aurum Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), under the terms of which Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation (the "Merger"), this option, which is fully vested, was cancelled in the Merger in exchange for a cash payment equal to $101.00 per share (without interest) minus the per share exercise price of the option.